Abstract
Pyridostigmine bromide (PB) is an inhibitor of cholinesterase, which is used in the treatment of myasthenia gravis and administered for protection against exposure to toxic nerve agents. Tests were done to investigate prolonging the half-life of PB and improving its release behavior. PB was loaded in nanoparticles (NPs) of Eudragit RS PO (Eu-RS) prepared using the technique of quasi emulsion solvent diffusion. Variables of output power of the sonicator, bath temperature and mixing time, were chosen as the optimization factors to obtain the minimum sized NPs. In addition, emulsions were tested at different ratios of drug-to-polymer by dynamic light scattering to determine size and zeta potential of NPs. UV-spectroscopy was used to determine PB content of the NPs. Drug-loaded NPs were characterized by scanning electron microscopy, X-ray diffraction, and Fourier transform infrared spectra. Results determined that mixing time had a significant impact on the size of Eu-RS NPs, but power output of sonicator and bath temperature had no significant effect. The particle size obtained at the optimum condition (power output of 70 W, bath temperature of 33 °C, and mixing time of 7 min) was less than 200 nm (optimum sizes were 138.9 and 179.5 nm for Eu-RS and PB-loaded Eu-RS NPs, respectively). The optimum PB-loaded Eu-RS NPs at the PB to Eu-RS weight ratio of 1–4 and 20 % of loaded PB released from the nanocarriers within 100 h.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adibkia K, Alaei-Beirami M (2012) Evaluation and optimization of factors affecting novel diclofenac sodium–Eudragit RS100 nanoparticles. Afr J Pharm Pharmacol 6:941–947
Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Kari Niri F, Alaei-Beirami M (2011) Naproxen–Eudragit RS100 nanoparticles: preparation and physicochemical characterization. Colloids Surf B 83:155–159
Bolourchian N, Rangchian M, Foroutan M (2012) Prolonged release matrix tablet of pyridostigmine bromide: formulation and optimization using statistical methods. Pak J Pharm Sci 25:607–616
Dillen K, Vandervoort J, Van den Mooter G, Ludwig A (2006) Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm 314:72–82
Eidi H, Joubert O, Némos C, Grandemange S, Mograbi B, Foliguet B, Tournebize J, Maincent P, Le Faou A, Aboukhamis I, Rihn B (2012) Drug delivery by polymeric nanoparticles induces autophagy in macrophages. Int J Pharm 422:495–503
Hegazy N, Demirel M, Yazan Y (2002) Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int J Pharm 242:171–174
Huang Y, Tsai T, Cheng C, Cham T (2007a) Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigation of in vitro/in vivo dissolution properties. Drug Dev Ind Pharm 33:403–416
Huang Y, Cheng C, Lai T, Tsai T, Chuo W, Cham T (2007b) An investigation of acetylcholine released in skeletal muscle and protein unbound drug released in blood based on the pyridostigmine bromide (pretreatment drug) sustained-release pellets by microdialysis technique in the rabbit model. Neurosci Lett 416:302–306
Huang Y, Tsai T, Cheng C, Cham T (2007c) Formulation design of an HPMC-based sustained release tablet for pyridostigmine bromide as a highly hygroscopic model drug and it’s in vivo/in vitro dissolution properties. Drug Dev Ind Pharm 33:1183–1191
Kawashima Y, Niwa T, Handa T, Takeuchi H, Iwamoto T, Itho K (1989) Preparation of controlled-release microspheres of ibuprofen with acrylic polymer by a novel quasi-emulsion solvent diffusion method. J Pharm Sci 78:68–72
Lopedota A, Trapani A (2009) The use of Eudragit RS 100/Cyclodextrin nanoparticles for the transmucosal administration of glutathion. Eur J Pharm Biopharm 72:509–520
Mandal B (2010) Preparation and physicochemical characterization of Eudragit® RL100 nanosuspension with potential for ocular delivery of sulfacetamide. The Master of Science Thesis. Pharmaceutical Sciences. The University of Toledo
Pignatello R, Bucolo C (2002a) Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 91:2636–2641
Pignatello R, Bucolo C (2002b) Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53–61
Rastegar SO, Mousavi SM, Shojaosadati SA, Sheibani S (2011) Optimization of petroleum refinery effluent treatment in a UASB reactor using response surface methodology. J Hazard Mater 197:26–32
Sahoo SK, Panyam J, Prabha S, Labhasetwar V (2002) Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82(1):105–114
Sieb J, Köhler W (2010) Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin Neurol Neurosurg 112:781–784
Tan Q, Wang N, Yang H, Zhang L, Liu S, Chen L, Liu J, Zhang L, Hu N, Zhao C, Zhang J (2010) Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm 384:165–172
Tan Q, Xu ML, Wu JY, Yin HF, Zhang JQ (2012a) Preparation and characterization of poly(lactic acid) nanoparticles for sustained release of pyridostigmine bromide. Pharmazie 67:311–318
Tan Q, Hu N, Liu G, Yin H, Zhang L, Wang H, Lu L, Zhang J (2012b) Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. Arch Pharm Res 35:499–508
Yang M, Cui F, You B, Fan Y, Wang L, Yue P, Yang H (2003) Preparation of sustained-release nitrendipine microspheres with Eudragit RS and aerosol using quasi-emulsion solvent diffusion method. Int J Pharm 259:103–113
Zhang J, Zhang Z, Yang H, Tan Q, Qing S, Qiu X (2005) Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res 22:573–583
Acknowledgments
The authors are grateful to Stat-Ease, Minneapolis, MN, USA, for the provision of the Design Expert package.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoobakht, F., Ganji, F., Vasheghani-Farahani, E. et al. Eudragit RS PO nanoparticles for sustained release of pyridostigmine bromide. J Nanopart Res 15, 1912 (2013). https://doi.org/10.1007/s11051-013-1912-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11051-013-1912-y